Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 6Phase 2/3 3Phase 1 3Phase 4 1Phase 3 1Phase 1/2 1

Status

Terminated 6Completed 6Active not recruiting 5Recruiting 4Unknown 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1

Conditions

Neoplasms 87Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 73Recurrence 64Colorectal Neoplasms 63Pancreatic Neoplasms 60Melanoma 58Advanced Solid Tumor 57Carcinoma, Hepatocellular 56Multiple Myeloma 55Lymphoma 53Leukemia, Myeloid, Acute 53Advanced Solid Tumors 53Neoplasm Metastasis 50Stomach Neoplasms 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma, B-Cell 40Solid Tumor 39Ovarian Neoplasms 38Lymphoma, Non-Hodgkin 38Lung Neoplasms 36Glioblastoma 35Prostatic Neoplasms 34Leukemia 28Head and Neck Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 26Uterine Cervical Neoplasms 25Burkitt Lymphoma 24Esophageal Neoplasms 23Urinary Bladder Neoplasms 20

Interventions

blinatumomab 2Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Neoplasm, Residual × Clear all
NCT06125106 2023-11-09

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Zhejiang University

Phase 1 Unknown
31 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Celularity Incorporated

Phase 1 Unknown
29 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasm, Residual, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04604691 2022-03-08

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Seoul National University Hospital

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡